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Abstract 
Up-to-date pharmacological topics for inclisiran and statin for dyslipidemia are described. The efficacy of inclisiran has been reported 
for reduction of LDL-C values. Inclisiran has been involved in gene silencing, which brings selective inhibition of a protein by 
targeting its mRNA. For RCTs of inclisiran, ORION 10/11 studies were conducted, where inclisiran and control groups were followed 
1.5 years. LDL-C reduced in 53.8%/49.2%. RCTs of 19 meta-analyses showed whether statins will prolong life and its degree. As a 
result, statin can delay onset of events compared to placebo for cardiovascular death 9.3 days, myocardial infarction 18 days, and 
stroke 6.1 days. 
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Commentary Article 
In actual clinical practice, metabolic syndrome is increasing 
worldwide. The underlying problem would be the presence of 
dyslipidemia. Concerning dyslipidemia, current topics can include 
inclisiran and other agents [1,2]. This paper introduces the latest 
reports and developments on dyslipidemia. As a new agent for 
dyslipidemia, the efficacy of inclisiran has been reported. It is 
used for patients associated with high LDL-C. For large studies, 
the ORION-10 and the ORION-11 tests were conducted. The 
former was intended for patients with atherosclerotic 
cardiovascular disease (ASCVD). The latter is intended for 
patients with ASCVD or at risk comparable to ASCVD. Both 
protocols were RCTs comparing two groups of inclisiran (284 
mg) and placebo for 1.5 years. Regarding the protocols, inclisiran 
was given by subcutaneous injection on the 1st and 90th days, 
and every 6 months thereafter. For the evaluation, the changed 
ratio in LDL-C was measured as the primary outcome. As a 
result, the LDL-C after 1.5 years was found to decrease by 53.8% 
in the former and 49.2% in the latter. All data were significantly 
different from placebo (p <0.001). In the light of adverse effects, 
some pain and swelling at the injection site were more common in 
the inclisiran group [2].  
Inclisiran has been involved in gene silencing, which brings 
selective inhibition of a protein by targeting its mRNA [1]. As to 
the safety of inclisiran, pre-specified analysis of ORION-1 was 
conducted, especially from hematological parameters [3]. 
Inclisiran is a siRNAs (small interfering RNA molecules) directed 
against PCSK9. It is indeed that its benefit is with large efficacy 
for lowering LDL-C, but weak point is expensive. Then, its use 
has been often discontinued, that may leave the patients keeping 
higher cardiovascular risk [4]. Inclisiran is an interfering RNA 
targeting PCSK9 (proprotein convertase subtilisin-kexin type 9). 
As to inclisiran, pharmacodynamic property was investigated for 
subjects with renal impairment and normal function [5]. As a 
result, both groups showed similar data, indicating no necessity of 
dose adjustments for renal function. Inclisiran has an unknown 
effect on cardiovascular prognosis at this stage [2]. Therefore, we 
look forward to the accumulation of evidence in the future. 
Conventionally, n-3 unsaturated fatty acids have been reported to 
have benefits for the cardiovascular system. Several systematic 
review meta-analyses in n-3 USFA have been reported. A recent 
review included a double-blind RCT 17 study (n=83,617) with a 
follow-up period of ≥1 year. When the dose of n-3 unsaturated 
fatty acids became higher, the benefits became greater. In other 
words, the risk reduction of cardiovascular disease was not 
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revealed at 1 g or less per day. Second, at 2 g daily, the rate of 
cardiac death was significantly reduced, with a relative risk (RR) 
0.55. Furthermore, when 3 g or more was administered daily, a 
significant reduction in risk was observed. Regarding the detailed 
RR, the remarkable effects were shown: cardiac death 0.82, 
sudden death 0.70, and stroke 0.74 [6].  
For elderly people with frailty, a systematic review was 
conducted on the cardiovascular prognosis of statins. Of these, 6 
cohort studies were included and RCTs meeting the acceptance 
criteria were not included. In addition, the results for 
cardiovascular events and the effects on primary prevention were 
not included. This included a study of the secondary prophylaxis 
population, which showed a reduced risk of death as HR 0.28 [7]. 
There is an ASPREE (Aspirin in Reducing Events in the Elderly) 
study that investigated the efficacy of statins in healthy elderly 
people. The results of this secondary analysis have recently been 
reported. ASPREE has been an RCT that examines the effect of 
aspirin on healthy life expectancy. The subjects were 19,114 aged 
65 and over, of which 18,096 aged 70 and over (median 74.2 
years, 56.0% female) were extracted in the secondary analysis. 
Among them, two groups were compared, between who were 
taking statins at the beginning of the study and those who were 
not. The investigated factors were survival condition without 
disability (combined outcomes of total mortality, dementia, and 
persistent physical dysfunction). Follow-up of 4.7 years in 
median found no significant difference between statin use and 
unimpaired survival as Hazard ratio (HR) 0.92. Thus, secondary 
analysis of RCTs showed little benefit of statins on healthy life 
expectancy [8]. Judging from this, the effects of statins on the 
general elderly will not necessarily be significant. There is a 
cohort study investigating statin treatment in the elderly for 
primary prevention of cardiovascular disease. Among them, the 
subjects were 326 thousand US veterans aged 75 and over. The 
average age was 81.1 years, 97% male and 91% Caucasian, with 
an average follow-up of 6.8 years. As a result, cardiovascular 
deaths per 1000 man-years were 22.6 for statin users and 25.7 for 
non-users. Corrected by propensity score matching, HR was 0.75 
total mortality, 0.80 cardiovascular mortality, and 0.92 
arteriosclerotic cardiovascular event. All of them were found to 
be significantly lower in statin users [9]. The results of RCTs 
analyzed the extent to which statins could prolong life, associated 
with the publication of 19 meta-analysis. The degree of delayed 
onset of events compared to placebo showed cardiovascular death 
9.3 days, non-cardiovascular death 1.5 days, myocardial 
infarction 18 days, and for stroke 6.1 days [10].  
Various factors were investigated that affect cardiac statins for 
medication adherence. A review was conducted in a systematic 
review associated with the summary reported. From detail 
examination of nine reviews, factors with positive effects on 
medication adherence were found to be high social/economic 
status, high education level, and age of middle-aged people. On 
the other hand, there were many factors related to the decrease in 
medication adherence. They include older, younger, female 
subjects, lower economic and social levels, higher out-of-pocket 
costs, new statin users as medication history, dosage/dose 
complexity, and experience of reverse effects. Psychologically, 
distrust of medical care and lack of realization of clinical effects 
were included, and lifestyle habits included daily drinking and 
smoking [11].  
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